Evaluation of XYA02 in Patients With Advanced Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.

Trial Details

NCT ID
NCT07670312
Phase
PHASE1 / PHASE2
Sponsor
XYone Therapeutics, Inc
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • XYA02
Locations (sample)
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Perth, Western Australia, Australia|-31.95224,115.8614

Key Eligibility Criteria

  • Signed informed consent form(s) (ICFs) obtained at Screening.
  • Has an eligible relapsed/refractory tumor with measurable disease based on RECIST 1.1 at Screening.
  • Age ≥18 years at Screening and confirmed at the discretion of the Investigator.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 at Screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →